Evidence map›Paper›PMID 26504901›Full record

ArticleDiscoveries (Craiova, Romania)

An updated h-index measures both the primary and total scientific output of a researcher.

Octavian Bucur, Alex Almasan, Roman Zubarev, Mark Friedman, Garth L Nicolson, Pavel Sumazin, Mircea Leabu, Barbara S Nikolajczyk, Dorina Avram, Tanja Kunej and 24 more

Abstract read
In one paragraph

Article in Discoveries (Craiova, Romania). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Multiplex flows in citation networks.Applied network science · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Octavian BucurDepartment of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA.
Alex AlmasanDepartment of Cancer Biology, Lerner Research Institute & Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Roman ZubarevDepartment of Medical Biochemistry & Biophysics, Karolinska Institutet, Stockholm, Sweden.
Mark FriedmanDepartment of Pathology, St. Luke's-Roosevelt Hospital Center, Beth Israel Medical Center and Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Garth L NicolsonDepartment of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA, USA.
Pavel SumazinDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Mircea LeabuDepartment of Cellular and Molecular Medicine, University of Medicine and Pharmacy Carol Davila and Victor Babes National Institute of Pathology, Bucharest, Romania.
Barbara S NikolajczykDepartment of Microbiology, Boston University School of Medicine Boston, MA, USA.
Dorina AvramDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USA.
Tanja KunejDepartment of Genetics, Animal Biotechnology and Immunology, Domzale, Slovenia.
George A CalinDepartment of Experimental Therapeutics and Leukemia & Center for RNA Interference and Non-Coding RNAs, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, University of Kansas Cancer Center Kansas City, KS, USA.
Hans-Olov AdamiDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Peter G ZaphiropoulosDepartment of Biosciences and Nutrition, Karolinska Institute, Sweden.
Des R RichardsonDepartment of Pathology and Bosch Institute, University of Sydney, Sydney, Australia.
Gerold Schmitt-UlmsDepartment of Laboratory Medicine & Pathobiology, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Håkan WesterbladDepartment of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Megan KeniryBiology Department, University of TEXAS Pan American, Edinburg, TX, USA.
Georges E R GrauDepartment of Pathology, University of Sydney, Sydney, Australia.
Salvatore CarbonettoCentre for Research in Neuroscience, McGill University Health Sciences Centre, Montreal, Canada.
Radu V StanThe Geisel School of Medicine at Dartmouth, Dartmouth College, Lebanon, NH, USA.
Aurel Popa-WagnerDepartment of Psychiatry, Rostock University Medical School, Rostock, Germany.
Kasumov TakharDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.
Beverly W BaronDepartment of Pathology, University of Chicago, Chicago, IL, USA.
Paul J GalardyPediatric Hematology/Oncology, Mayo Clinic Transplant Center, Mayo Clinic, Rochester, MI, USA.
Feng YangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Dipak DataBiochemistry Division, CSIR-Central Drug Research Institute, Lucknow, India.
Oluwole FadareDepartment of Pathology, University of California, San Diego, San Diego, CA, USA.
Kt Jerry YeoDepartment of Pathology, University of Chicago, Chicago, IL, USA.
Georgiana R GabreanuVictor Babes National Institute of Pathology and Biomedical Sciences, Bucharest, Romania.
Stefan AndreiService de Médecine Interne, CNHO des Quinze-Vingts, Paris, France.
Georgiana R SoareDepartament of Obstetrics and Gynaecology, Bucharest University Emergency Hospital, Bucharest, Romania.
Mark A NelsonDepartment of Pathology, The University of Arizona, Tucson, AZ, USA.
Elisa A LiehnInstitute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
Heartland Institute for Clinical and Translational ResearchUL1TR000001 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAROHN, RICHARD J. · 2012 to 2015
$13.0M
Fox Chase Clinical Epidemiology and Validation CenterU01CA113916 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ENGSTROM, PAUL FREDERICK · 2005 to 2015
$8.6M
Role of Bcl11b in CD4+ T cells and innate lymphoid cellsR01AI067846 · NIAID · UNIVERSITY OF FLORIDA · PI AVRAM, DORINA · 2007 to 2023
$6.2M
The Molecular Actions of Imatinib Mesylate in GISTsR01CA106588 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K., VON MEHREN, MARGARET · 2004 to 2013
$3.8M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
Novel computational methods for in vivo proteome dynamics estimation using heavy water metabolic labeling and LC-MSR01GM112044 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SADYGOV, ROVSHAN G · 2015 to 2023
$2.7M
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian CancerR01CA140323 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K. · 2010 to 2014
$2.1M
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagyR01CA184137 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI ALMASAN, ALEXANDRU · 2015 to 2019
$1.8M
NCATS NIH HHS UH2 TR000943NCATS NIH HHS UL1 TR000001NCI NIH HHS P30 CA023108NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA093459NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA106588NCI NIH HHS R01 CA140323NCI NIH HHS R01 CA151351NCI NIH HHS R01 CA182905NCI NIH HHS R01 CA184137NCI NIH HHS R21 CA172983NCI NIH HHS R21 CA186846NCI NIH HHS U01 CA113916NHLBI NIH HHS R21 HL114407NIAID NIH HHS R01 AI067846NIAID NIH HHS R21 AI112492NIGMS NIH HHS R01 GM112044
6 · The paper itself

Abstract

The growing interest in scientometry stems from ethical concerns related to the proper evaluation of scientific contributions of an author working in a hard science. In the absence of a consensus, institutions may use arbitrary methods for evaluating scientists for employment and promotion. There are several indices in use that attempt to establish the most appropriate and suggestive position of any scientist in the field he/she works in. A scientist's Hirsch-index (h-index) quantifies their total effective published output, but h-index summarizes the total value of their published work without regard to their contribution to each publication. Consequently, articles where the author was a primary contributor carry the same weight as articles where the author played a minor role. Thus, we propose an updated h-index named Hirsch(p,t)-index that informs about both total scientific output and output where the author played a primary role. Our measure, h(p,t) = h(p),h(t), is composed of the h-index h(t) and the h-index calculated for articles where the author was a key contributor; i.e. first/shared first or senior or corresponding author. Thus, a h(p,t) = 5,10 would mean that the author has 5 articles as first, shared first, senior or corresponding author with at least 5 citations each, and 10 total articles with at least 10 citations each. This index can be applied in biomedical disciplines and in all areas where the first and last position on an article are the most important. Although other indexes, such as r- and w-indexes, were proposed for measuring the authors output based on the position of researchers within the published articles, our simpler strategy uses the already established algorithms for h-index calculation and may be more practical to implement.

Identifiers

PMID26504901
PMCPMC4617786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.